Home/ Stocks/ VNRX

VolitionRX Limited Common Stock

VNRX XASE

$0.20 -0.00 (-2.09%) ▼ 15-min delayed

Open

$0.20

High

$0.21

Low

$0.19

Volume

3.06M

Market Cap

$27.85M

About VolitionRX Limited Common Stock

VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.

Sector: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES Employees: 48 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q3 2025	$627.3K	$-5,409,791	N/A
Q2 2025	$406.7K	$-6,314,070	N/A
Q1 2025	$246.4K	$-5,476,627	N/A
FY 2024	$1.23M	$-27,257,985	N/A

Earnings & Analyst Ratings

Next Earnings: Wed, May 13, 2026

Calendar →

Related Market News

No specific coverage for VNRX yet. Check out our latest market news or earnings calendar.

Get VNRX Alerts

Stay ahead with breaking news, price alerts, and expert analysis on VolitionRX Limited Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.